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Background
There is no consensus on the ideal methodology for eli-
citing participant-reported harms, but question methods
influence the extent and nature of data detected. This
gives potential for measurement error and undermines
meta-analyses of adverse effects. We undertook to iden-
tify barriers to accurate and complete reporting of
harms data, by qualitatively exploring participants’
experiences of illness and treatment, and reporting
behaviours; and compared the number and nature of
data detected by three enquiry methods.
Methods
Participants within antiretroviral/antimalarial interaction
trials in South Africa and Tanzania were asked about med-
ical history, treatments and/or adverse events by general
enquiries followed by checklists. Those reporting differ-
ently between these two question methods were invited to
an in-depth interview and focus group discussion. Health
narratives were analysed to investigate accuracy and com-
pleteness of case record form data and to understand rea-
sons for differential reporting between question methods.
Outcomes were the number and nature of data by ques-
tion method, themes from qualitative analyses and a theo-
retical interpretation of participants’ experiences.
Results
We observed a cumulative increase in sensitivity of
detection of all types of reports while progressing from
general enquiry, through checklist, to in-depth interview.
Questioning detail and terminology influenced partici-
pants’ recognition of health issues and treatments.
Reporting patterns and vocabulary suggest influence
from the relative importance that illnesses and treat-
ments have for participants. Perceptions were often
dichotomised (e.g. ‘street’ versus clinic treatments,
symptoms experienced versus tests and examinations
performed, chronic versus acute illness, persistent versus
intermittent symptoms, activity- versus malaria-related
symptoms) and this differentiation extended to ideas of
relevance to report. South African participants displayed
a ‘trial citizenship’, taking responsibility for the impact
of their reporting on trial results, and even reaching
reporting decisions by consensus. In contrast, Tanza-
nians perceived their role more as patients than partici-
pants; the locus of responsibility for knowing
information relevant to the trial fell with trial staff as
doctors rather than with themselves.
Conclusions
Our observations of how reporting relates to participant
perceptions inside and outside trials could help optimise
how harms data are elicited. Questions reflecting the
different ways that biomedically defined illness and
treatment data are perceived by participants may help
them understand relevance for reporting. We will theo-
rise how these two disparate trial environments may
have influenced how participants understood their role,
as this could help researchers achieve empowered parti-
cipation in similar trials.
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